EGFR-Targeted ADC Therapy After Chemotherapy and Immunotherapy
For patients with recurrent or metastatic nasopharyngeal carcinoma, treatment can become increasingly difficult after the cancer has progressed through platinum chemotherapy and PD-1 immunotherapy.
Becotatug vedotin, also known as MRG003, provides a different treatment strategy.
It is an EGFR-targeted antibody-drug conjugate, or ADC.
EGFR is frequently expressed on nasopharyngeal carcinoma cells. The antibody portion of becotatug vedotin recognizes EGFR, attaches to the cancer cell and delivers a linked cytotoxic agent directly into the tumor cell.
This allows treatment to combine the selectivity of antibody targeting with the cell-killing activity of chemotherapy.
In China, becotatug vedotin received its first approval for adults with recurrent or metastatic nasopharyngeal carcinoma who had failed at least two lines of systemic chemotherapy as well as PD-1 or PD-L1 inhibitor therapy.
A multicenter phase II study evaluated the therapy in previously treated recurrent or metastatic nasopharyngeal cancer.
The independently assessed objective response rate was approximately 42%, while the disease control rate reached approximately 81%.
Median duration of response was about 8 months, median progression-free survival approximately 5.8 months, and median overall survival approximately 15.8 months across the overall study population.
These results are particularly relevant because the participants had limited remaining standard treatment options.
Patients who may be evaluated include those with:
- Recurrent or metastatic nasopharyngeal carcinoma
- Progression after platinum-based systemic therapy
- Previous exposure to PD-1 or PD-L1 immunotherapy
- Disease not suitable for curative surgery or radiotherapy
- Adequate physical condition for further systemic treatment
Because ADCs still deliver a potent cytotoxic payload, they can cause significant adverse effects. Blood counts, liver function and neurologic symptoms should be monitored.
For patients whose nasopharyngeal carcinoma has progressed after both chemotherapy and immunotherapy, EGFR-directed ADC treatment offers a mechanistically different option rather than simply repeating another conventional chemotherapy regimen.
